Physician profile
Amanda E Bohleber
NPI 1306981394
$3,530.92
in general payments reported to CMS, 2019-2025
18 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.84 · 2020: $47.24 · 2021: $842 · 2022: $49.43 · 2023: $1,402 · 2024: $1,045 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,141 · Debt Forgiveness: $936 · Food and Beverage: $449 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,140.61 |
| Debt Forgiveness | $936.25 |
| Food and Beverage | $449.12 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Midmark Corporation | $2,032.05 | 2021-2023 | |
| Optos, INC. | $936.25 | 2024 | Panoramic Ophthalmoscope |
| Glaxosmithkline, LLC. | $141.82 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $92.44 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $61.74 | 2022-2025 | |
| Amgen INC. | $51.76 | 2020-2024 | Evenity, Prolia |
| Novo Nordisk INC | $28.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.26 | 2024 | |
| Inspire Medical Systems, INC. | $17.07 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $15.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.97 | 2020 | |
| Lundbeck LLC | $14.47 | 2025 | Rexulti |
| Csl Behring | $14.21 | 2023 | Hizentra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bohleber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.